跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
TEVA-DEFERASIROX - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
TEVA-DEFERASIROX
Authorized
STANDARD
TEVA-DEFERASIROX
teva canada limited
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
423e62755d3e04fa
Company
teva canada limited
Type
Standard
Approval Details
Approval Id
423e62755d3e04fa
Drug Approval Canada Name
TEVA-DEFERASIROX
Product Name
TEVA-DEFERASIROX
Status
Cancelled Post Market
Status Date
2020-06-07
Original Market Date
2017-06-26
Din
02407973
Drug Class
Human
Dosage Form
Tablet For Suspension
Route Of Administration
Oral
Schedule
Prescription
Ahfs
64:00.00
Atc Original
V03AC03 DEFERASIROX
Atc Name
v 03 ac 03
Aig Number
0151733003
Company Name
teva canada limited
Company Address
30 Novopharm Court, Toronto, Ontario, Canada, M1B 2K9
Active Ingredients
DEFERASIROX
500 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
423e62755d3e04fa
Type
Standard
Back to Health Canada Approvals